Sparian begins Phase I trial for pain relief with SBS-147

Sparian Biosciences has launched a Phase I trial of SBS-147, an oral AEA receptor agonist aimed at improving pain management. The study will evaluate safety, tolerability, and pharmacokinetics in healthy adults, marking a step toward new treatments for acute and chronic pain.

Sparian Biosciences has officially started a Phase I clinical study of SBS-147, a novel aryl epoxamide receptor (AEA) agonist aimed at treating both acute and chronic pain conditions. This trial represents an initial human evaluation of a compound designed to broaden therapeutic options in pain management beyond currently available treatments. SBS-147 has been formulated for oral administration, which aims to enhance dosing flexibility compared with prior generations of similar molecules.

Development Background of SBS-147

The SBS-147 program is built upon the earlier candidate SBS-1000, which was developed for acute pain management. SBS-1000 has already completed a Phase I single ascending dose (SAD) trial using a parenteral formulation and continues to be developed for acute pain indications. SBS-147 represents the next iteration in chemical design and pharmacological approach, offering an oral route of administration and a broader range of potential applications.

Design and Objectives of the Phase I Trial

The Phase I study of SBS-147 incorporates both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The primary goals of the trial are to assess tolerability, pharmacokinetics, and safety in healthy adult participants. By including both SAD and MAD arms, researchers aim to generate comparative initial human data across different exposure levels, while maintaining a safety-focused framework typical of early-stage clinical studies.

Funding and Institutional Support

The development of SBS-147 from Phase I into Phase II is financially supported by a grant from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) under the HEAL Initiative. The awarded funding for this stage totals $15 million USD. This grant constitutes the second phase of public support for this development pathway and represents the fifth NIH/NIDA award received by Sparian Biosciences, bringing the total government funding for its programs to approximately $75 million USD.

Academic Collaboration

Professor Susruta Majumdar of Washington University in St. Louis has contributed to the discovery and development of both SBS-147 and SBS-1000. His participation connects the academic research perspective with the biopharmaceutical development pipeline of the AEA agonist program.

Company Statement and Strategic Context

Dr. Jeffrey Reich, CEO of Sparian Biosciences, stated that SBS-147 builds on the foundation established by the first-generation AEA agonist, SBS-1000. The oral formulation is expected to improve dosing flexibility and expand the potential clinical applications to include both acute and chronic pain management. Dr. Reich emphasized that effective pain management remains a major challenge in surgical and clinical care settings and that SBS-147 aims to address areas not sufficiently served by current therapies, including opioid-based treatments.

The company highlighted that AEA agonists may provide a viable alternative to opioid medications, particularly in light of the ongoing opioid crisis. Sparian also noted its commitment to returning to clinical studies with next-generation AEA agonists and stressed the importance of translating preclinical results into early human trials, specifically with the orally administered SBS-147 candidate.

Key Points

• Initiation of Phase I study for SBS-147, an AEA receptor agonist
• Focus on oral administration with enhanced dosing flexibility
• Trial structure includes both SAD and MAD cohorts in healthy volunteers
• Primary endpoints: tolerability, pharmacokinetics, and safety
• SBS-1000 has completed Phase I SAD parenteral study and continues development for acute pain
• Development supported by $15 million NIH/NIDA HEAL Initiative grant
• Total government funding for Sparian programs approximately $75 million across five awards
• Academic collaboration with Professor Susruta Majumdar of Washington University in St. Louis

Sources:

• Fierce Biotech
• Clinical Trials Arena
• BioSpace
• Sparian commences Phase I trial of SBS-147 for pain treatment